Dr. Shang Song's research lab at the University of Arizona focuses on understanding and treating spinal cord injuries (SCIs) through innovative neuromodulation techniques. The lab aims to develop personalized treatments that use electrical stimulation to enhance neural circuit plasticity, promote motor recovery, and alleviate pain for individuals suffering from SCIs. The approach is based on training the spinal circuitry to work better, ultimately improving the quality of life for those affected by these injuries.

Dr. Joseph Stayman's lab focuses on improving the accuracy and standardization of radiomics, which are models that help in diagnosing diseases like interstitial lung disease using medical imaging. By developing a mathematical framework, the lab seeks to reduce errors associated with different imaging protocols and devices, ultimately enhancing the reliability of imaging biomarkers. This research is crucial for leveraging large patient image databases for better disease classification and patient outcomes.

Dr. Patrick S. Stayton's lab focuses on developing innovative therapies for respiratory infections, particularly those caused by coronaviruses and antibiotic-resistant bacteria. By utilizing advanced biomaterials and drug delivery systems, the lab aims to create inhalable treatments that can target lung infections effectively and improve outcomes for patients, especially in crises like pandemics. Their research seeks to revolutionize how we combat pulmonary pathogens through targeted drug delivery and combination therapies.

Dr. Zhongming Liu's research lab focuses on understanding how the brain and stomach communicate with each other, especially in relation to feelings and digestion. By studying the intricate neural circuits that connect these two systems, the lab aims to map their interactions and how they affect overall health and well-being. This research could lead to better treatments for various mental and digestive disorders.

Dr. Chun Yuan's lab at the University of Washington focuses on advancing techniques in MRI to better understand and classify ischemic strokes. By developing automated analysis tools, their research aims to provide clearer diagnostics for stroke patients, particularly those with unclear causes, allowing for more targeted treatment options. The lab integrates state-of-the-art imaging and machine learning methods to enhance stroke prevention strategies.

Dr. Erik Sulman's research lab focuses on understanding and overcoming radiation resistance in glioblastoma, a severe type of brain cancer. By exploring how glioblastoma stem-like cells change states, the lab aims to find new ways to make these cancer cells more sensitive to radiation therapy. The research combines advanced genetic techniques with clinical data to develop better treatment strategies for patients suffering from this challenging disease.

Dr. Michael R. Tadross's lab at Duke University focuses on advancing neuropharmacology to improve treatments for neuropsychiatric disorders. The lab is developing an innovative technology called DART, which allows for precise drug delivery to specific types of brain cells in a noninvasive way. By understanding and targeting the cellular mechanisms of behavior, the team aims to transform how we study brain disorders and enhance treatment options for patients.

Dr. Cheemeng Tan's lab at UC Davis focuses on studying extracellular vesicles (EVs), which are tiny particles that cells release to communicate with each other. By using synthetic biology techniques, the lab aims to create new EV mimetics that can be used as drug delivery systems. This research could help refine the therapeutic use of EVs and make them more effective for treating diseases by enhancing their production and consistency.

Eric Tanifum's lab at Baylor College of Medicine focuses on understanding and treating Parkinson's disease through innovative approaches. The lab is developing nano-sized scavengers that target misfolded proteins implicated in the disease to both diagnose and treat it. By using techniques like advanced imaging and cellular analysis, they aim to uncover new methods for slowing or halting disease progression.

Dr. Mukherjee's lab at UC Irvine focuses on developing innovative imaging agents to help diagnose and understand Alzheimer's disease. The primary goal is to create novel tracers that can bind to Tau proteins, which are critical in understanding the progression of this neurodegenerative disease. By utilizing advanced imaging techniques like PET and SPECT, the lab aims to improve early detection and treatment strategies for Alzheimer's and related disorders.

Dr. Paul Territo's research lab at Indiana University focuses on understanding neuroinflammation in Alzheimer's disease and related dementias. The lab studies P2X7 receptors, which play a significant role in communication between brain cells and are involved in the inflammatory processes that lead to neurodegeneration. By investigating these mechanisms using advanced mouse models, the lab aims to develop potential treatments to prevent cognitive decline associated with these diseases.

Dr. Avnesh Sinh Thakor's research lab at Stanford University focuses on innovative therapies for transplant medicine and kidney injury. The lab develops new biomaterials and cell-based therapies to enhance the survival and function of transplanted islets and to treat acute kidney injury through mesenchymal stem cells. By incorporating advanced technologies, the lab aims to improve outcomes for patients undergoing these challenging medical treatments.

Dr. Taylor H Ware's lab focuses on developing innovative solutions for stress urinary incontinence (SUI) in women. They are creating a new type of dynamic midurethral sling that can change shape and support dynamically, helping to improve patient comfort and reduce complications compared to current static options. This research integrates engineering and biology to create smarter medical devices that better meet patients' needs.

Dr. Abhinav K Jha's lab focuses on enhancing cancer treatment through advanced imaging techniques. Specifically, they are developing a new method for quantitative imaging of alpha-particle therapies, which are promising treatments for metastatic cancers like prostate cancer. The research aims to accurately measure how much of these therapies are absorbed in both cancerous and healthy tissues, ultimately improving treatment personalization and effectiveness for patients.

Dr. Patricia Ribeiro Pereira's lab focuses on improving cancer treatments, specifically for breast and gastric cancers. They are exploring innovative antibody-drug conjugates that enhance drug delivery to tumor cells, especially in cases where tumors have developed resistance to standard therapies. By using special antibody pairs that can bind more effectively to cancer cells, the lab aims to make existing treatments more effective and potentially prevent drug resistance in the future.

Dr. Tatiana Segura's lab at Duke University focuses on developing innovative biomaterials to aid recovery after ischemic stroke. By utilizing extracellular vesicles from activated astrocytes, the lab explores new therapies that promote brain repair and regeneration instead of merely protecting against damage. The ultimate goal is to create effective treatments that target the underlying issues of stroke-related disabilities, offering new hope for patients.

Dr. Patrick M. Boyle's lab focuses on understanding the mechanisms behind strokes related to heart conditions, specifically those involving fibrosis in the left atrium. Using advanced computer simulations and medical imaging, the lab aims to uncover how changes in heart structure and function contribute to stroke risks. Their goal is to develop a personalized risk assessment tool that will help improve stroke prevention strategies for patients who have atrial fibrillation or other risk factors.

Tal Danino's research lab focuses on developing innovative bacterial therapies to enhance cancer treatments, particularly for triple-negative breast cancer. By engineering probiotic bacteria to deliver therapeutics directly to tumors, the lab aims to overcome the limitations of traditional immunotherapy, offering safer and more effective options for patients. They utilize advanced synthetic biology techniques to create systems that allow these bacteria to selectively release drugs at the tumor site.

Dr. Ho-Ling Anthony Liu's lab focuses on improving the way we map and understand critical brain functions for patients undergoing surgery for conditions like brain tumors and epilepsy. They are developing innovative software tools that enhance the analysis of brain imaging data, allowing for more accurate localization of important brain areas without relying on patients to perform specific tasks. Their work aims to increase the number of patients who benefit from advanced brain imaging techniques, ultimately improving surgical outcomes and preserving vital brain functions.

Dr. Albert Folch's lab focuses on advancing cancer treatment through innovative drug testing technologies. By integrating microfluidics with advanced biosensors, they aim to create platforms that simulate the tumor microenvironment, allowing for more accurate testing of cancer therapies. Their work strives to enhance personalized medicine and improve the success rate of drug therapies, especially immunotherapies.